ANTIBIOTICS

ANTIFUNGALS

NUTRITIONAL ADDITIVES

COLORING AGENTS

BIOACTIVE COMPOUNDS

ANTIOXIDANTS

PIGMENTS

ANTIOXIDANTS

INNOVATIVE AND NATURALLY-SOURCED ACTIVE MOLECULES FOR HEALTH, NUTRITION AND COSMETICS

1

DEINOVE HARNESSES

BIOLOGICAL DIVERSITY TO

DEVELOP INNOVATIVE

COMPOUNDS FOR SUCCESSFULL

APPLICATIONS IN THE HEALTH,

NUTRITION AND COSMETICS

INDUSTRIES

2

2006

2010

Year of creation

Listed on Alternext

since

50 Staff

6,000Proprietary strains

160Patent applications

20 €m market cap

sq. metres of laboratories1,500

DEINOVE AT A GLANCE

NATURE AND TECHNOLOGY WORKING AS ONE

3

• Healthcare

• Industrial biotech

• New antibiotics

• Carotenoids (antioxidants, pigments)

• Nutritional additives

• Bioactive compounds

B to B company

• Provides ingredients

• Provides technologies for making ingredients:

tailor-made solutions to partner

• Health

• Nutrition

• Cosmetics

Product

pipeline

57 B$ in 2018(Future Market Insights & BCC)

COSMETICS

- Antioxidants (carotenoids)

- Bioactive compounds

- Pigments…131 B$ in 2019(Euromonitor)

NUTRITION

- Antioxidants

- Coloring agents (carotenoids)

- Nutritional additives, etc.109 B$ in 2020(MarketsandMarkets)

Business model

Key assets

Core

businesses

Target markets

• Strain collection

• Cutting-edge technologies and highly-skilled

staff: strain development, fermentation

• 160 patents

HEALTH

- Antibiotics

- Antifungals 57 B$ in 2018(Future Market Insights & BCC)

SOLUTIONS FOR HEALTH

Microorganisms are the most efficient antibiotics producers of the living world

… but the discovery of new antibiotics is challenged by the almost exhaustive use of the same

kinds of bacteria

The Deinove strain collection offers a great potential for accessing new

molecules of therapeutic value

6,000 strains that have not been explored so far

Many bacterial phyla represented: Actinobacteria, Proteobacteria, Bacteroidetes, Firmicutes…

Continuous enrichment of this strain collection using innovative, creative and proprietary

selection methods

The Deinobiotics subsidiary is dedicated to finding new antibiotic structures to

fight multi-resistant pathogens

Exploring novel bacterial genera as new sources

NEW ANTIBIOTICS TO FIGHT RESISTANT INFECTIOUS STRAINS

4

THE CHALLENGE OF ANTIMICROBIAL RESISTANCE

AN INCREASINGLY URGENT MEDICAL NEED

A GLOBAL HEALTH CHALLENGE

Antimicrobial resistance (AMR) could cause

10 million deaths/year by 2050 (World Health

Organization)Today 700 000 deaths/year

… WITH LITTLE REMEDIAL SOLUTIONS AVAILABLE

Deaths attributable to antimicrobial resistance every

year compared to other major causes of death – WHO

19

11 11 11

43

1

1980-1984 1985-1989 1990-1994 1995-1999 2000-2004 2005-2009 2010-2012

Since the early 80’s, the number of antibiotic molecules supplied to the market has dropped dramatically

Approved new antibiotic applications

BIG PHARMAS ARE NOW ACTIVELY

LOOKING FOR NEW MOLECULES

Call from the United Nations on 21/09/16

5

DNB 101

A FIRST PROMISING CANDIDATE

Novel chemical structure

New class of antibiotics

Activity against dangerous

antibiotic-resistant bacteria,

identified as a priority by public

health authorities

Ongoing tests: efficacy,

pharmacology…

Preparing for preclinical

development

Two patents

VALIDATES THE POTENTIAL OF DEINOVE’S BACTERIA AND PLATFORM

AS A SOURCE OF NEW CLASSES OF ANTIBIOTICS

6

BUILDING A TRUE PIPELINE

EFFICIENTLY ADDRESSING THE CONCERN OF MULTI-RESISTANCE

DNB 101

DNB 10X

Collection of new

strains with creative

and proprietary

methods

Robotized extract

production

Smart way to detect antimicrobial activities

(TLC-bioautography)

Enhancement of the production of secondary

metabolites

Deep expertise in mass spectra analysis and

proprietary LIMS to identify compound

Fermentation capacities for a quick

production of samples POC & ADME

DNB 102

Powerful three-pronged approach:

1. Genetic engineeringIdentification of the cluster of genes involved in the

biosynthesis

explore other bacteria for this family of compounds

change properties of the compound

2. Medicinal chemistry

3. Enzymology

THE AIM IS NOW TO MOVE TOWARDS AN AUTOMATED YET INNOVATIVE APPROACH

THAT IS INTENDED TO MULTIPLY THE NUMBER OF DRUG CANDIDATES

7

SOLUTIONS FOR NUTRITION

Food and feed markets are driven by demographic growth and diet changes

33% worldwide population increase by 20501

Animal health have become key for accessing safe food

Consumer concern for health and quality => replacing oil-based additives by natural compounds

DEINOVE strains offer a wide range of compounds of interest

Antioxidants (health claims)

Coloring agents (pigments)

Nutritional additives (proteins, enzymes, etc.)

Two development paths

Partnerships with industrial producers for easier access to market

Self-sustained development of some specific compounds (carotenoids) for higher margins

NATURAL AND EFFICIENT NUTRIENTS FOR FOOD AND FEED

8

1 United Nations

PARTNERSHIPS IN ANIMAL NUTRITION AND HEALTH

CUSTOMER-DRIVEN

• 17-month R&D partnership with FLINT HILLS

RESOURCES, a US leader in refining, petrochemicals and

biofuels – a subsidiary of KOCH INDUSTRIES

• Production of ingredients for animal feed

• If successful, both partners will study the terms of a

licensing agreement

• FHR covers the costs of the project

• 3-year collaboration contract with AVRIL Group, leading

player of the vegetable oils and protein sectors

• Develop a process for producing natural supplements for

animal feed

• First two steps successfully completed: the effectiveness

and bioavailability of the ingredients developed by

DEINOVE have been validated

• Aim: industrialize the production and launch a new range

of products for animal feed

9

Step I Step II Step III

Aug.

2014

May

2015

S1

2018

Fermentation optimization,

extraction, characterization,

preliminary tests on animals

Process optimization

Scale up

Regulatory process

Srenning, 20

strains selected

Step I Step II Step III

Nov.

2015

May

2018

Process optimization

for the selected strain(s)

Efficacy studies

Scale up

Sreening, 10 strains

pre-selected,

confirmation of

interest from FHR

CAROTENOIDS PROGRAM

PERFORMANCE-FOCUSED

AIM

• Offer a competitive bio-based alternative for

manufacturers by developing a range of natural

carotenoids and offering significant advantages in

terms of supply stability, consistent high quality,

conservation of natural resources and also costs

• Several monetization strategies:

> Royalty-based license agreement

> Direct sale of compounds (toll-manufacturing)

• No significant investment in equipment required

R&D OUTCOMES

• > 100 strains sequenced and annotated

• X 10 increased fermentative capacity

• Development of the metabolic pathway,

increased number of target molecules: POC

for the production of 5 different carotenoid

compounds

• Optimized producer strains: up to 8 fold

increased yields

10

Step I Step II Step III

Jan.

2014

Feb.

2016

Feb.

2017

Target selection

Optimize strains (yield,

stability) and fermentation

conditions

Design the extraction and

purification process

Product formulation

Scale-up

Develop the metabolic

pathway: 5 molecules

produced at lab-scale

Oct.

2016

Step IV

Evaluate the functional

properties of compounds

Regulatory process

Q3

2018

Goal:

1st batches

marketed in 2018

CAROTENOIDS

SPECIALTY MOLECULES OF HIGH ADDED-VALUE

11

PROPERTIES

• Antioxidant

• Coloring

APPLICATIONS

• Food supplements

• Coloring agents for food and feed

• Cosmetic ingredients

MARKET 1

• $ 1.8B in 2019

• Selling price: 300-3,000€/kg

• Production price: 200-600€/kg

24%

21%

16%

14%

10%

7%8%

Astaxanthin CapsanthinLutein Beta-caroteneAnnatto LycopeneOther

1 BCC research

3.9%CAGR

Today’s megatrend: stay healthy and retain a youthful look as time passes by

All the more true as population is aging.

Cosmetic market is driven by innovation…

A constantly evolving world : players are always looking for innovative and effective formulas to

offer efficient, safe and attractive products to the consumer.

…and naturality

+10% CAGR for global natural cosmetics1

SOLUTIONS FOR COSMETICS

A MARKET RELYING ON INNOVATION

12

1 Kline

SOLUTIONS FOR COSMETICS

A CATALOG OF COSMETIC ACTIVE EXTRACTS

13

Antioxidant

Anti-aging

UV protection…

Healing

Anti-aging

Damaged skin…

Lipid storage

Moisturizing effet

Plumping effect…

Anti-inflammatory

Sensitive/irritated skin

Post-operative skin care…

Lipolysis

Slimming

Anti-cellulite…

Dozen of

DEINOVE’s strains

with confirmed

properties

SOLUTIONS FOR COSMETICS

Co-develop and market new active ingredients for skin care

AN AMBITIOUS PARTNERSHIP

14

Major player in the production and distribution of biotechnologically obtained ingredients

Sells a hundred active ingredients derived from biodiversity to cosmetics manufacturers in over 30 countries

Objective:

A commercial launch

by end of 2018

MERGING BIOLOGY AND TECHNOLOGY

15

A COLLECTION OF 6,000 STRAINS

A UNIQUE BIODIVERSITY

16

Deinococcus

Others

Bacillus

Microbacterium

Arthrobacter

Rhodococcus

Delftia

Micrococcus

Paenibacillus

Pseudomonas

Curtobacterium

Cellulomonas

Microvirgula

Cellulosimicrobium

Kocuria

Leifsonia

Stenotrophomonas

Lactococcus

Brevibacillus

Cupriavidus

Enterobacteriaceae

Serratia

Sporosarcina

4 years of harvesting in

numerous hostile environments:

deserts, glaciers, hot springs, volcanoes, lagoons…

1,200 collection points

A patented selection method

using UV radiation

6,000 strains

available

2,500

Deinococcus

strains

3,500 other rare

and

extremophile

bacteria

A COLLECTION OF 6,000 STRAINS

Non-GMO strains producing novel compounds for a wide range of applications

A UNIQUE BIOLOGICAL SOURCE OF NOVEL COMPOUNDS

17

Antibiotics

Pigments

Antioxidants

Oligo-

saccharides

Antifungals

Lipids

Anti-ageing

EnzymesProteins

Moisturizers

DEINOCOCCUS, ONE OF THE OLDEST LIFE FORMS ON EARTH

SURVIVES IN VERY HOSTILE ENVIRONMENTS (HOT SPRINGS, GLACIERS, VOLCANOES…) AND RESISTS EXTREME CONDITIONS

18

A MECHANISM THAT CAN

REPAIR ITS DNA WITHIN

12-24 HOURS

RADIOACTIVE EXPOSURE: >1,000

TIMES MORE THAN HUMANS

MULTIPLE COPIES OF

GENOME: 4 TO 10

NON PATHOGENIC ; CLASS 1

DEHYDRATION AND

DESICCATION

(VIABLE AFTER 2 YEARS OF

DESICCATION)

DEINOVE is the sole company leveraging this extraordinary ability displayed by “hyper

resistant” micro-organisms.

The Company screens for and recovers compounds that enable the body to better

withstand external aggressions.

The genome is shattered into hundreds of pieces. It is a dead cell. But out of this horrendous

damage, Deinococcus can resurrect”. Miroslav Radman, cofounder of DEINOVE

ENGINEERING BIOLOGY

CUTTING-EDGE TECHNOLOGIES, HIGHLY QUALIFIED STAFF

19

COLLECTION AND AUTOMATED

PRODUCTION OF EXTRACTS

CUTTING EDGE

ANALYTICAL PLATFORM

IN VITRO SCREENING• Test the strains

• Identify interesting features,

production of compounds of

interest

FERMENTATION

EXTRACTION, PURIFICATION• Test and optimize the production process

in increasing volumes

• Produce extracts for testing (efficacy,

pharmacological properties…)

AUTOMATED GENETIC

ENGINEERING• Optimize the strain for end use:

yield, biodisponibility…

• Determine the structure of compounds

produced (antibiotics, carotenoids)

• Analyze the strain metabolism for

optimization purpose

• 6,000 Deincocccus strains

and other rare bacteria

• Culture, selection and

production of extracts

• Sequencing

MOLECULES

OF INTEREST

EXCLUSIVE TECHNOLOGY PROTECTED BY PATENTS

A BASIS TO CREATE VALUE

20

22 families

of patent

Strain

collection

Cultivating

methods

Screening

methods

Engineering

methods

End-use

applications

CORPORATE

21

INCOME GENERATION

A B TO B INDUSTRIAL BIOTECH COMPANY

WITH A CAPITAL-LIGHT BUSINESS MODEL

22

POTENTIAL

PARTNERS

• Industrial

companies

operating in

targeted markets

• Suppliers of

ingredients

RESEARCH PROJECTS

Structuring and screening of the bacteria bank

Strainoptimizationaccording to the applications

Fermentation tests in the laboratory

Extraction, purification

Characterization of the molecules produced

Economic analysis and regulatory validations

Scaling up to the industrial pilot

(sub-contracting)

R&D

Partner financing

Public institutions

Marketing

Technology licenses

(non-exclusive or limited exclusivity)

Sale of batches of finished products

(e.g. carotenoids)

ANTIBIOTIC DEVELOPMENT BACKED BY FINANCIAL PARTNERS

• Early stages

• Supported by DEINOVE

Stand alone

• Public support (Bpifrance, BARDA, IMI, H2020, EIB…)

• Grants from foundations (Wellcome Trust, Gates Foundation…)

Institutional supports • Product development risk

sharing with big pharma/major biotech companies

• Drug sale

• Partial transfer of rights

Pharma deals

OPPORTUNITY FOR NON DILUTIVE FINANCING

Discovery Lead optimization Preclinical Clinical

23

Stable net loss: -6.3 €m (vs. -6.4 €m in 2015)> Tight control over operating expenses: +0,3%, while DEINOBIOTICS project has been fully

reintegrated into DEINOVE

Cash burn under control:

Cash position +9.3 €m (vs. +12.4 €m at end of 2015)> Stable operating expenses: (7,750 €k) ; investments (770 €k) ; Subscription for DEINOBIOTICS

bonds (500 €k)

> Increased income: 2nd and 3rd milestones DEINOCHEM – Ademe (2,264 €k); Worldwide Innovation

Challenge – Bpifrance (140 €k); 4th milestone DEINOL (948 €k); Research tax credit 2015 (1,6 €k);

revenues from collaboration agreements (793 €k) - AVRIL, FLINT HILLS RESOURCES; Equity line

(780 €k)

> Cash resources to finance its projects until the end of the 1st quarter of 2018, without

resorting to Tranches 3 and 4 of the equity line funding

24

FINANCIAL DATA – 2016

MANAGEMENT TEAM

25

Emmanuel PETIOTCEOFormerly, Commercial Director of NOVOZYMES North America Inc.

EDHEC Business School, École Centrale Paris

Julien COSTECFOFormerly Director of Finance & Administration at Neuro3D then the French branch of the Publicis Healthcare Communication Group (PHCG).

ESC Grenoble, Master 2 in IT Management, Paris Dauphine

Coralie MARTINCommunication and IRFormerly in charge of marketing at Pierre Fabre and bioMérieuxChili

INSA Toulouse, IAE Lyon

Marie BÉZENGERDirector of OperationsFormerly Director of Operations at Fermentalg; 20 years at Chr. Hansen

Polytech Montpellier, PhD in Biochemistry, Cell and Molecular Biology, University of Montpellier

Dominique LE BELLERCEO of DeinobioticsCo-founded NovexelAntibiotic research at Aventis

Biological Engineer; PhD in Microbiology, Bioconversions and Enzymology, University of Technology of Compiègne

Johane RINALDI Human ResourcesFormerly Human resources manager at Bausch + Lomb

University of Lyon

BOARD OF DIRECTORS

26

Christian PIERRETFormer French Minister

of Industry

Dr Philippe POULETTYCo-founderFounder and Managing partner

TRUFFLE CAPITAL

Michael CARLOSDirector

GIVAUDAN

Dr Charles WOLERChairmanVice-Chairman GENFIT

Bernard FANGETVP Process Development and

Manufacturing ABIVAX

Pr Vincent JARLIERHead of Dpt of Bacteriology

and Hygiene

PITIÉ-SALPÊTRIÈRE HOSPITAL

Dr Yannick PLÉTANClinical development specialist

PIERRE FABRE, PFIZER, ROCHE

27

Market capitalization evolution since the IPO (April 2010)

Shareholders’ structure at 31.12.16 (diluted)

Market data

Market cap: €22m

Share price: €2.1

Average volume 60,000

in 2017: shares/day

Indexes:

ALTERNEXT ALLSHARE

ENTERNEXT PEA-PME 150

ENTERNEXT TECH 40

OSEO INNOVATION

27,6%

3,3%

3,3%65,7%

Funds managed by Truffle Capital Scientific founders

Management & Board members Free float

Broker Price target Date

Edison €8 13.05.16

Invest Securities €4 10.04.17

Portzamparc €5.6 29.09.16

€ million

CAPITAL AND SHARE PERFORMANCE

DEINOVE

DEINOVE is building on its strengths…

• A unique and highly diversified source of compounds with potential interest

• Expert in the Deinocccus bacterial chassis

• Technological platform and expertise to accelerate the development of compounds of interest

• Financial resources

• High-level scientific and management team ; new experienced board members

To focus on higher value markets

• Health, with a 1st lead targeting a market with urgent medical need: antibiotic resistance

• Nutrition, with already 2 partnerships that are demonstrating their value

• Cosmetics, with the Carotenoids program and a partnership in the field

IN A NUTSHELL

28

And generate revenues faster

CONTACTS

29

Montpellier, FRANCECAP SIGMAZAC Euromédecine II1682 rue de la Valsière34790 GRABELSwww.deinove.com

Emmanuel PETIOTCEOTel.: + 33 6 13 80 25 30emmanuel.petiot@deinove.com

Coralie MARTINCommunication, Marketing and Investor Relations ManagerTel.: + 33 4 48 19 01 60coralie.martin@deinove.com